ketazolam / Generic mfg. - LARVOL DELTA

Comparative stability assessment of designer benzodiazepines and methaqualones in dry blood spots and blood using UHPLC-MS/MS: Implications for forensic applications. (PubMed, Forensic Sci Int) - "Furthermore, specific degradation products were identified, such as diazepam from ketazolam and 7-aminoclonazolam from clonazolam. DBS cards frequently provide equal or improved stability compared to whole blood, particularly in short-term analyses. Consequently, securing biological material in both forms is recommended to maximize analytical options in forensic and toxicological investigations."

Journal

Sex differences of fall-risk-increasing drugs in the middle-aged and elderly: a descriptive, cross-sectional study of FDA adverse event reporting system. (PubMed, Sci Rep) - "For males, the top 3 signals with the highest ROR were fluprednidene acetate, potassium hydroxide, ketazolam (ROR: 216.86, 108.43, 108.43), while the top 3 signals with the highest IC025 were clomethiazole, piribedil, melperone (IC025: 3.31, 3.24, 2.99). We offered a series of FRIDs and suggested their sex differences in falls through the FAERS. In the future, it is essential to balance the inclusion of women and men, and analyse sex-stratified for FRIDs."

Adverse events • Journal • Observational data • Retrospective data • Cardiovascular • Musculoskeletal Diseases

Repurposing FDA-approved drugs against multiple proteins of SARS-CoV-2: An in silico study. (PubMed, Sci Afr) - "Remdesivir, Lopinavir and Hydroxychloroquine were used as reference drugs. Ligands that bound all target proteins, and showed the lowest binding energies with good ADMET properties and particularly showed the lowest binding against ACE2 are ethynodiol diacetate (-15.6 kcal/mol), methylnaltrexone (-15.5 kcal/mol), ketazolam (-14.5 kcal/mol) and naloxone (-13.6 kcal/mol). Further investigations are recommended for ethynodiol diacetate, methylnaltrexone, ketazolam and naloxone through preclinical and clinical studies to ascertain their effectiveness."

FDA event • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases